Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models

详细信息    查看全文

• 作者：Makiko Yamashita ; Takashi Nonaka ; Tetsuaki Arai ; Fuyuki Kametani ; Vladimir L. Buchman ; Natalia Ninkina ; Sergey O. Bachurin ; Haruhiko Akiyama ; Michel Goedert ; Masato Hasegawa
• 关键词：Tau ; Alpha-synuclein ; Inhibitor ; Alzheimer ; ALS ; FTLD
• 刊名：FEBS Letters
• 出版年：2009
• 出版时间：21 July 2009
• 年：2009
• 卷：583
• 期：14
• 页码：2419-2424
• 全文大小：1438 K

文摘

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are major neurodegenerative diseases with TDP-43 pathology. Here we investigated the effects of methylene blue (MB) and dimebon, two compounds that have been reported to be beneficial in phase II clinical trials of Alzheimer’s disease (AD), on the formation of TDP-43 aggregates in SH-SY5Y cells. Following treatment with 0.05 μM MB or 5 μM dimebon, the number of TDP-43 aggregates was reduced by 50 % and 45 % , respectively. The combined use of MB and dimebon resulted in a 80 % reduction in the number. These findings were confirmed by immunoblot analysis. The results indicate that MB and dimebon may be useful for the treatment of ALS, FTLD-U and other TDP-43 proteinopathies.